Psychedelic Therapy For Anxious Depression
The effectiveness of intravenous Psychedelic Therapy in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence
Background: Individuals meeting criteria for treatment-resistant depression (TRD) are differentially affected by high levels of anxiety symptoms.
Aims: There is a need to identify the efficacy of novel rapid-onset treatments in adults with mood disorders and comorbid anxious-distress.
Methods: This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) Psychedelic Therapy treatment at a community-based clinic. Anxious-distress was proxied using items from the Quick Inventory of Depressive Symptomatology–Self Report 16-item (QIDS-SR16) and Generalized Anxiety Disorder 7-item (GAD7) scales. The difference in QIDS-SR16 total score, QIDS-SR16 suicidal ideation (SI) item and GAD7 score were analyzed between groups.
Results: A total of 209 adults with MDD (n = 177) and BD (n = 26) were included in this analysis. From this sample, 94 patients (mean = 45 ± 13.9 years) met the criteria for anxious-distress. Individuals meeting the criteria for anxious-distress exhibited a significantly greater reduction in QIDS-SR16 total score following four infusions (p = 0.02) when compared with patients not meeting the anxious-distress criteria. Both anxious-distressed and low-anxiety patients exhibited a significant reduction in SI (p < 0.0001) following four infusions. Finally, there was a significantly greater reduction in anxiety symptoms in the anxious-distress group compared with the non–anxious distress group following three (p = 0.02) and four infusions (p < 0.001).
Conclusion: Patients with TRD and prominent anxiety receiving IV Psychedelic Therapy exhibited a significant reduction in depressive, SI and anxiety symptoms.
Download Full Publication
Related Articles
-
Symptom Response to Repeat Dose Intravenous Psychedelic Therapy in Adults with Major Depressive and Bipolar Disorder
Orly Lipsitz
Journal of Affective Disorders , 2021
Multiple studies have demonstrated antidepressant effects of intravenous (IV) Psychedelic Therapy for unipolar and bipolar treatment-resistant depression (TRD). However, these studies have not delineated which specific symptoms of depression are more commonly improved by IV Psychedelic Therapy.
Read More -
Safety and tolerability of IV Psychedelic Therapy in adults with major depressive or bipolar disorder
Nelson B. Rodrigues
Expert Opinion on Drug Safety (Taylor & Francis) , 2020
Rigorous clinical trials suggest Psychedelic Therapy is safe and well-tolerated in patients with treat-ment-resistant depression (TRD). There is a paucity of data on the safety and tolerability of Psychedelic Therapy in community-based clinics treating patients with TRD.
Read More -
Oral Psychedelic Therapy for Depression
Joshua D. Rosenblat, MD
The Journal of Clinical Psychiatry (J Clin Psychiatry) , 2019
Intravenous (IV) Psychedelic Therapy has rapid and robust antidepressant effects; however, poor accessibility of the IV route often limits its use Numerous alternative routes of administration are being investigated. Oral Psychedelic Therapy is particularly appealing for its ease of use with the potential for high accessibility.
Read More
